Lexaria Bioscience Corp (LEXX): Price-to-Revenue Ratio

Symbol and logo of brand Lexaria Bioscience (LEXX)

Lexaria Bioscience (LEXX) is recognized as a leading innovator due to its DehydraTECH system, as confirmed by this chart. Fluctuations in the P/S multiple demonstrate market sentiment, while the 46.80 indicator reflects current dynamics. The business model relies on royalties from global partners, ensuring seamless scalability. However, the volatility of licensing payments and competition from tech giants create certain risks for the company's sustainability.

LEXX Lexaria Market Cap to Revenue (07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for Lexaria Bioscience (LEXX)

- share price and consensus valuation forecast:
Price Performance Chart lexariabioscience.com|LEXX - Price Target Chart
- stock exchange capitalization data:
Market Value Lexaria|LEXX - Enterprise Value
- issuer book value statistics:
Net Asset Value per Share Lexaria Bioscience|LEXX - Company Net Assets|Capitalization to Book Value Ratio lexariabioscience.com|LEXX - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Lexaria Bioscience|LEXX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital lexariabioscience.com|LEXX - Company Aggregate Debts|Debts to Net Assets Lexaria|LEXX - Company Long-Term Debts|Company Short-Term Debts Lexaria Bioscience|Intermediate Coverage Ratio lexariabioscience.com
- earnings and multiples data:
LEXX - Net Profit|Expected Profit Lexaria Bioscience|LEXX - P/E Multiple|Market Cap to Projected Earnings lexariabioscience.com|LEXX - Price/Earnings to Growth Ratio|Company Value to EBITDA Lexaria|LEXX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Lexaria Bioscience|LEXX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months lexariabioscience.com|LEXX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Lexaria Bioscience
- sales revenue and business income indicators:
LEXX - Revenue and Sales Volume|Company Expected Sales Volume lexariabioscience.com|LEXX - Price-to-Revenue Ratio|Market Cap to Projected Revenue Lexaria
General company analysis:LEXX, Lexaria Bioscience Corp
Signature product of Lexaria Bioscience Corp.

The P/S ratio determines the market value of a company relative to its annual sales volume. This metric compares market capitalization to revenue, allowing an investor to assess the premium paid per unit of income. By analyzing the price-to-sales ratio, one can detect market overheating of an asset in a timely manner. For Lexaria Bioscience (LEXX), such a valuation reflects market expectations regarding the commercialization of DehydraTECH technology within the drug delivery sector.

Competing companies

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue KVUE|Verona Pharma PLC - Price-to-Revenue Ratio|Jyong Biotech Corp - P/S Multiple|Price to Sales Ligand Corp|AMRX (Amneal Pharmaceuticals) - Market Cap to Revenue|Market Cap to Revenue Ratio PRGO|ALVO (Alvotech SA) - P/S Multiple|P/S Multiple Liquidia Corp|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP (ANI Pharmaceuticals Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple MNKD (MannKind Corporation)|Price-to-Revenue Coefficient amphastar.com (AMPH)|Pacira BioSciences, Inc. - P/S Multiple|SPRY - P/S Multiple|TBPH (Theravance) - Market Cap to Revenue|Aquestive Corp - Market Capitalization-to-Revenue Ratio|SCPH (scPharmaceuticals, Inc.) - P/S Multiple|Price-to-Revenue Ratio TECX|P/S Multiple TNXP|Price-to-Revenue Coefficient sxtchina.com|Price-to-Revenue Ratio Eupraxia Pharmaceuticals Inc. EPRX|BioHarvest Sciences Inc (BHST) - Price to Sales|EXOZ - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Oramed Pharmaceuticals ORMP|ENTX: P/S Multiple|Market Cap to Revenue MindWalk Holdings, Inc.|ABVC (ABVC BioPharma Inc) - P/S Multiple|Cumberland Corp (CPIX) - Price-to-Revenue Coefficient|P/S Multiple QNTM|FGEN - Price to Sales|Price-to-Revenue Ratio Telomir Pharmaceuticals, Inc. TELO|RANI: Market Cap to Revenue Ratio|Synergy CHC Corporation - P/S Multiple|Rallybio Corporation (RLYB) - Market Cap to Revenue|PULM: P/S Multiple|Price to Sales Pheton Holdings (PTHL)|Price-to-Revenue Ratio Aptorum Group Ltd|Price-to-Revenue Ratio LYRA|P/S Multiple IBO|TNFA - Price to Sales|cbdMD - Market Cap to Revenue|PRFX: Market Cap to Revenue Ratio|CYTO: Market Cap to Revenue|LIPO (Lipella Pharmaceuticals Inc) - Market Cap to Revenue Ratio|Optinose (OPTN) - Price-to-Revenue Ratio|Price-to-Sales Ratio PIRS (Pieris Pharma)|PROC (Procaps Group S.A.) - P/S Multiple|PTPI: Market Capitalization-to-Revenue Ratio|P/S Multiple QLI|P/S Multiple Acelyrin Inc. (SLRN)|Price-to-Revenue Ratio TFF Pharma TFFP